Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · IEX Real-Time Price · USD
9.19
+0.05 (0.55%)
Apr 26, 2024, 1:22 PM EDT - Market open
Theravance Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 - 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.42 | 51.35 | 55.31 | 71.86 | 73.41 | 60.37 | 15.39 | 48.65 | 42.13 | 11.69 | Upgrade
|
| Revenue Growth (YoY) | 11.84% | -7.17% | -23.03% | -2.12% | 21.61% | 292.37% | -68.37% | 15.48% | 260.42% | 5071.68% | Upgrade
|
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0.72 | 6.03 | 2.89 | 4.66 | 4.06 | Upgrade
|
| Gross Profit | 57.42 | 51.35 | 55.31 | 71.86 | 73.41 | 59.66 | 9.36 | 45.75 | 37.47 | 7.63 | Upgrade
|
| Selling, General & Admin | 70.1 | 67.07 | 99.3 | 108.53 | 106.08 | 97.06 | 95.59 | 84.51 | 90.2 | 71.65 | Upgrade
|
| Research & Development | 40.62 | 63.39 | 193.66 | 260.95 | 219.25 | 201.35 | 173.89 | 141.71 | 129.17 | 168.52 | Upgrade
|
| Other Operating Expenses | 2.74 | 12.84 | 20.14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Operating Expenses | 113.46 | 143.3 | 313.1 | 369.48 | 325.33 | 298.41 | 269.48 | 226.22 | 219.37 | 240.17 | Upgrade
|
| Operating Income | -56.04 | -91.96 | -257.78 | -297.63 | -251.92 | -238.75 | -260.12 | -180.47 | -181.9 | -232.54 | Upgrade
|
| Interest Expense / Income | 2.35 | 6.37 | 8.55 | 8.55 | 31.86 | 10.48 | 8.55 | 1.4 | 0 | 0 | Upgrade
|
| Other Expense / Income | -9.12 | -1,149.44 | -66.75 | -19.64 | -42.1 | -23.15 | 3.04 | -1.31 | -0.63 | -1.87 | Upgrade
|
| Pretax Income | -49.27 | 1,051 | -199.58 | -286.54 | -241.68 | -226.09 | -271.71 | -180.56 | -181.27 | -230.67 | Upgrade
|
| Income Tax | 5.92 | 178.98 | -0.15 | -8.52 | -5.22 | -10.56 | 13.69 | 10.11 | 0.95 | 6.36 | Upgrade
|
| Net Income | -55.19 | 872.13 | -199.43 | -278.02 | -236.46 | -215.52 | -285.41 | -190.67 | -182.22 | -237.04 | Upgrade
|
| Shares Outstanding (Basic) | 55 | 74 | 69 | 62 | 56 | 54 | 52 | 45 | 34 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 74 | 69 | 62 | 56 | 54 | 52 | 45 | 34 | 32 | Upgrade
|
| Shares Change | -24.85% | 5.95% | 11.41% | 12.11% | 3.04% | 3.09% | 17.09% | 30.93% | 7.54% | 0.04% | Upgrade
|
| EPS (Basic) | -1.00 | 11.85 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | Upgrade
|
| EPS (Diluted) | -1.00 | 11.85 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | Upgrade
|
| Free Cash Flow | -27.97 | -185.7 | -211.26 | -256.96 | -241.37 | -120.09 | -203.46 | -101.12 | -171.5 | -178.26 | Upgrade
|
| Free Cash Flow Per Share | -0.51 | -2.52 | -3.04 | -4.12 | -4.34 | -2.23 | -3.89 | -2.26 | -5.02 | -5.61 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 98.82% | 60.81% | 94.05% | 88.95% | 65.28% | Upgrade
|
| Operating Margin | -97.58% | -179.09% | -466.06% | -414.19% | -343.14% | -395.48% | -1690.65% | -370.96% | -431.80% | -1989.55% | Upgrade
|
| Profit Margin | -96.11% | 1698.54% | -360.55% | -386.90% | -322.08% | -357.01% | -1854.97% | -391.94% | -432.56% | -2028.05% | Upgrade
|
| Free Cash Flow Margin | -48.71% | -361.66% | -381.95% | -357.59% | -328.78% | -198.92% | -1322.36% | -207.87% | -407.12% | -1525.17% | Upgrade
|
| Effective Tax Rate | - | 17.03% | - | - | - | - | - | - | - | - | Upgrade
|
| EBITDA | -40.77 | 1,065 | -182.44 | -269.94 | -200.15 | -211.12 | -259.36 | -176.04 | -178.28 | -227.4 | Upgrade
|
| EBITDA Margin | -70.99% | 2074.53% | -329.85% | -375.66% | -272.63% | -349.71% | -1685.71% | -361.86% | -423.20% | -1945.59% | Upgrade
|
| Depreciation & Amortization | 6.15 | 7.71 | 8.59 | 8.05 | 9.67 | 4.48 | 3.8 | 3.12 | 2.99 | 3.27 | Upgrade
|
| EBIT | -46.92 | 1,057 | -191.03 | -277.99 | -209.82 | -215.6 | -263.16 | -179.16 | -181.27 | -230.67 | Upgrade
|
| EBIT Margin | -81.71% | 2059.53% | -345.37% | -386.87% | -285.80% | -357.14% | -1710.41% | -368.27% | -430.30% | -1973.60% | Upgrade
|